Drug Combination Details
| General Information of the Combination (ID: C58578) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Azacitidine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Myelodysplastic syndromes
[ICD-11: 2A36]
|
Phase 2 | [1] | ||
|
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Phase 1 | [2] | |||
|
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [3] | |||
|
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CEBPA | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | HNF1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | RHOH | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | XAF1 | Molecule Info | ||
| In-vitro Model | 8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| XG-7 | CVCL_A772 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. | |||||
